William Blair analyst Myles Minter has reiterated their neutral stance on MRNA stock, giving a Hold rating on April 14.
Myles Minter has given his Hold rating due to a combination of factors related to Moderna’s current market position and future prospects. One key consideration is the recent update by the CDC’s Advisory Committee on Immunization Practices (ACIP) regarding RSV vaccinations, which now includes high-risk adults aged 50-59. However, Moderna’s mRNA-based RSV vaccine, mRESVIA, is only approved for adults aged 60 and above, limiting its immediate market expansion.
Furthermore, while Moderna has submitted a supplementary Biologics License Application (sBLA) for mRESVIA to cover high-risk adults aged 18-59, the approval process is still pending with a PDUFA date set for June 12, 2025. This creates uncertainty about the vaccine’s future market potential. These factors, combined with the competitive landscape where other companies like Pfizer and GlaxoSmithKline have vaccines approved for broader age groups, contribute to the Hold rating as the company navigates these regulatory and market challenges.
In another report released on April 14, Jefferies also maintained a Hold rating on the stock with a $30.00 price target.